The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform ...

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...